McMurray, John J.V.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,686

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 1,663

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,599

A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study

Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine

Atrial Fibrillation Management and OutcomesCardiac Health and Mental Health

Cited by 1,562

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases

Endorsed by: the European Stroke Organisation (ESO), Authors/Task Force Members, Tendera, M., Aboyans, V., Bartelink, M.-L., Baumgartner, I., Clément, D., Collet, J.-P., Cremonesi, A., De Carlo, M., et al. (2011) · European Heart Journal

Peripheral Artery Disease ManagementVascular Procedures and Complications

Cited by 1,506

Rosuvastatin in older patients with systolic heart failure

Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthHeart Failure Treatment and Management

Cited by 1,487

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery

Atrial Fibrillation Management and OutcomesClinical practice guidelines implementation

Cited by 1,403

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,393

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine

Renin-Angiotensin System StudiesChronic Kidney Disease and Diabetes

Cited by 1,319

Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 1,240

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,020

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Verma, S., & McMurray, J. J. V. (2018) · Diabetologia

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 999

SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 996

Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure

Hillege, H. L., Nitsch, D., Pfeffer, M. A., Swedberg, K., McMurray, J. J. V., Yusuf, S., Granger, C. B., Michelson, E. L., Östergren, J., Cornel, J. H., et al. (2006) · Circulation

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 945

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 893

Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK

Conrad, N., Misra, S., Verbakel, J. Y., Verbeke, G., Molenberghs, G., Taylor, P. N., Mason, J., Sattar, N., McMurray, J. J. V., McInnes, I. B., et al. (2023) · The Lancet

Systemic Lupus Erythematosus ResearchChronic Disease Management Strategies

Cited by 879

Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 761

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation

Statistical Methods in Clinical TrialsPharmacovigilance and Adverse Drug Reactions

Cited by 750

Dilated cardiomyopathy

Schultheiss, H.-P., Fairweather, D., Caforio, A. L. P., Escher, F., Hershberger, R. E., Lipshultz, S. E., Liu, P. P., Matsumori, A., Mazzanti, A., McMurray, J., et al. (2019) · Nature Reviews Disease Primers

Cardiomyopathy and Myosin StudiesViral Infections and Immunology Research

Cited by 720

Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology

Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 708

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 694

Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure

Solomon, S. D., Dobson, J., Pocock, S., Skali, H., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Young, J. B., Michelson, E. L., et al. (2007) · Circulation

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 681

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 680

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Packer, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2015) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 673